Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health salivary hormone testing Coverage | O…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Salivary Hormone Testing

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Oscar Health's coverage stance and clinical guidance for salivary steroid hormone testing (e.g., cortisol, estrogens, progesterone, androgens) including indications, limitations, and scientific background for providers submitting claims.

    Policy Summary
    PayerOscar Health
    PolicySalivary Hormone Testing
    Policy CodePolicy N/A
    Change TypeTechnical/No material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain at least two late-night salivary cortisol (LNSC) measurements when using LNSC as initial biochemical testing for suspected Cushing syndrome.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Indication meeting criteria
    9+Proprietary vendors discussed
    MultipleProfessional societies cited
    No FDA-approvedRegulatory status
    4 listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Example procedure codes

    Coverage Criteria for Salivary Hormone Testing

    inv-01: Initial testing for suspected Cushing syndrome

    Covered when ALL of the following are met for the specified indication:

    LNSC for Cushing syndrome: Late-night salivary cortisol testing meets criteria for individuals with signs and symptoms of Cushing syndrome.At least two measurements obtained; diagnosis typically requires at least two abnormal first-line tests

    LNSC is a first-line diagnostic test and should be obtained at least twice; diagnosis of Cushing syndrome is established when at least two different first-line tests are abnormal (e.g., LNSC and 24-hour urinary free cortisol).

    inv-02: Not medically necessary uses

    Not covered for the following clinical purposes due to lack of sufficient evidence:

    Excluded indications: Screening, diagnosis, and/or monitoring of menopause, infertility, endometriosis, polycystic ovary disease (PCOS), premenstrual syndrome, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or diseases related to aging.

    Salivary hormone testing does not meet criteria for these indications.

    inv-03: Use of salivary hormone testing for individualized hormone therapy or monitoring

    Not supported by major professional societies when used to individualize hormone therapy or determine dosing:

    Primary rationale: Major professional societies (AACE; ACOG/ASRM; NAMS; Endocrine Society) state salivary hormone testing is inaccurate, unreliable, not standardized, and lacks evidence to guide individualized hormone therapy.

    See society guidance for details.

    Methodological concerns: Reported issues include low hormone concentrations in saliva, contamination, diurnal variation, intra- and inter-individual variability, absence of accepted reference ranges, and lack of independent quality control.

    These limitations undermine clinical utility for individualized dosing.

    Regulatory status: No FDA‑approved salivary or urinary steroid hormone tests; many assays are laboratory-developed tests regulated under CLIA as high‑complexity LDTs.

    Regulatory status affects validation and interpretation of results.

    inv-04: Diagnostic use for Cushing's syndrome/adrenal disorders

    Recommended use-case in certain diagnostic contexts:

    Cushing's diagnosis: Endocrine Society recommends at least two late-night salivary cortisol (LNSC) measurements for diagnosis of Cushing's syndrome; LNSC may also be used in post‑operative surveillance when assessment of eucortisolism is needed.>=2 measurements

    Follow guideline-recommended diagnostic steps and obtain multiple LNSC measurements as part of initial biochemical testing.

    Salivary steroid hormone testing is limited in scope under this policy. It meets criteria only for late‑night salivary cortisol (LNSC) testing in individuals with signs or symptoms of Cushing syndrome (see diagnostic criteria), and is otherwise considered not to meet criteria for many common clinical applications. Specifically, salivary hormone testing does not meet criteria for the screening, diagnosis, or monitoring of menopause, infertility, endometriosis, polycystic ovary syndrome (PCOS), premenstrual syndrome, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or conditions related to aging due to insufficient published evidence of clinical benefit.

    Professional society guidance and agency statements indicate that salivary hormone testing should not be used to determine dosing for compounded menopausal hormone therapy or to tailor individualized hormone therapy. Statements from ACOG/ASRM and NAMS conclude that salivary assays lack accuracy and precision for this purpose, that salivary levels are unreliable due to large intra‑patient variability and pharmacokinetic differences, and that saliva‑based dosing decisions are not supported by current evidence.

    Use of salivary hormone testing to individualize hormone replacement therapy or to guide sex steroid dosing is not supported. Major societies note methodological limitations — including low hormone concentrations in saliva, potential contamination, circadian and other biologic variability, and lack of standardized reference ranges — which prevent reliable interpretation of salivary sex steroid measurements for dosing decisions.

    Testing salivary hormone levels for the purpose of guiding individualized hormone replacement therapy or dosing, including for compounded bio‑identical hormone preparations, is considered not supported and therefore does not meet criteria. Society guidance emphasizes that salivary testing is inaccurate, unreliable, and not standardized for dose titration, and that serum testing — when needed — is preferred.

    Procedure Codes and Diagnostic Cut-offs

    Procedure codes referencedCPT | HCPCS | mixed
    82530Cortisol; free.
    82533Cortisol; total.
    S3650Saliva test, hormone level; during menopause.
    0462UMelatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary Proprietary Test: Salimetrics® Salivary Melatonin Profile (Circadian Phase Assessment)
    Selected diagnostic cut-offs mentioned
    Bedtime LNSC cut-off (children, LC-MS/MS)2.4 nmol/L (bedtime salivary cortisol cut-off used as screening threshold in children)
    LNSC concordance with 24‑hour urinary free cortisol97% concordance at ≥4 nmol/L (and 69% at ≥10 nmol/L); tests considered equivalent at 4 nmol/L)
    Study LNSC sensitivity/specificity example100% sensitivity and 98% specificity at a cut-off of 2.4 nmol/L (study reported)
    Stimulated salivary cortisol cut-off for adrenal insufficiency (SST comparison)13.2 nmol/L (stimulated salivary cortisol cut-off reported by Kim et al. 2020)
    Post-cosyntropin salivary cortisol threshold (LC‑MS/MS)>=12.6 nmol/L at 60 minutes post-cosyntropin to rule out adrenal insufficiency (Kvam Hellan et al. 2024)

    Provider Responsibilities, Authorization, and Testing Recommendations

    Prior Authorization

    Authorization and medical necessity

    Services must meet authorization and medical necessity guidelines; coverage decisions depend on the member's benefit coverage at the time of the request and applicable state/federal regulations.

    Billing Rule

    Procedure code reference and PA applicability

    Procedure codes listed in the policy (e.g., 82530, 82533, S3650, 0462U) are provided for reference; prior authorization requirements should follow payer rules for laboratory testing and any applicability of LDT regulation.

    • Example codes: 82530, 82533, S3650, 0462U

    Background and Scope

    Salivary testing has been proposed as a noninvasive method to measure the free (unbound) fraction of steroid hormones (e.g., cortisol, estrogens, progesterone, androgens). Proponents suggest saliva reflects unconjugated hormone concentrations and could be used for diagnosis or monitoring. However, the evidence shows variable analytical validity across hormones: cortisol (particularly late‑night salivary cortisol) has supporting data for screening of hypercortisolism, while salivary sex steroid measurements demonstrate poor correlation with serum, large within‑patient variability, and methodological challenges (low concentrations, contamination, and diurnal effects) that limit clinical utility.

    Definitions and Abbreviations

    LNSC — Late night salivary cortisol
    DefinitionLate-night salivary cortisol (LNSC): a salivary cortisol measurement taken late at night used as a screening/diagnostic test for Cushing syndrome.
    Recommended useEndocrine Society recommends at least two LNSC measurements for diagnosis of Cushing syndrome and supports LNSC as a first-line test in initial biochemical testing.
    Concordance/utilityLNSC has high concordance with 24‑hour urinary free cortisol at certain cut-offs (e.g., 97% concordance at ≥4 nmol/L) supporting its use as a frontline screening test.
    LC-MS — Liquid chromatography with tandem mass spectrometry
    DefinitionLC-MS: Liquid chromatography with tandem mass spectrometry — an analytical method used to quantify salivary steroids (LC‑MS/MS).
    Analytical preference
    Policy Summary
    PayerOscar Health
    PolicySalivary Hormone Testing
    Policy CodePolicy N/A
    Change TypeTechnical/No material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain at least two late-night salivary cortisol (LNSC) measurements when using LNSC as initial biochemical testing for suspected Cushing syndrome.
    SourceLink
    On This Page
    Coverage Criteria for Salivary Hormone TestingProcedure Codes and Diagnostic Cut-offsProvider Responsibilities, Authorization, and Testing RecommendationsBackground and ScopeDefinitions and Abbreviations
    Note

    LNSC as first-line biochemical test for suspected Cushing syndrome

    For individuals with signs and symptoms of Cushing syndrome, late-night salivary cortisol (LNSC) is described as a first-line diagnostic test and meets criteria when used for this indication.

    • LNSC identified as a first-line diagnostic test for Cushing syndrome
    Step Therapy

    Recommended testing approach for Cushing's syndrome

    The Endocrine Society recommends obtaining at least two late-night salivary cortisol (LNSC) measurements for diagnosis of Cushing syndrome; diagnosis is established when at least two different first-line tests are abnormal.

    • Obtain LNSC measurements at least twice
    • Diagnosis typically requires two abnormal first-line tests (e.g., LNSC and 24‑hour urinary free cortisol)
    Documentation Required

    Provider responsibility for accurate documentation and coding

    Providers are responsible for submission of accurate documentation of services performed and appropriate coding according to industry-standard coding guidelines; failure to do so may result in denial or recoupment.

    • Code claims according to CPT, HCPCS, ICD-10, UB, and CMS guidelines as applicable
    Documentation Required

    Documentation for LDT salivary assays

    If ordering laboratory-developed salivary assays, document that the assay is regulated under CLIA as a high-complexity LDT and include the clinical rationale, test name, and methodology (when available).

    • Document LDT status (CLIA high-complexity)
    • Include clinical rationale and test methodology (e.g., ELISA, LC‑MS/MS) and test name when available
    Denial Risk

    Denial risk for noncompliance with coding/billing or coverage rules

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed, or if services do not meet authorization and medical necessity guidelines.

    • Follow payer-specific reimbursement and coding policies to avoid denials or recoupment
    Denial Risk

    Unsupported use for individualized hormone dosing

    Use of salivary hormone testing to guide individualized hormone therapy or determine dosing is unsupported by professional societies and may trigger denial or non-coverage when billed for that purpose.

    • Professional guidelines (ACOG/ASRM, Endocrine Society) state salivary testing is not accurate or precise for individualizing therapy
    Mass spectrometry (LC‑MS/MS) is the more reliable method for quantifying salivary sex steroids versus immunoassays; methodological studies recommend LC‑MS/MS for valid salivary sex steroid measurement.
    Use in studiesLC‑MS/MS was used in pediatric LNSC studies and in establishing diagnostic cut-offs for salivary cortisol and cortisone after stimulation.
    LDTs — Laboratory-developed tests
    DefinitionLDTs: Laboratory-developed tests — assays that laboratories develop and validate in-house.
    RegulationLDTs are regulated under CLIA as high-complexity tests and are not FDA-approved or cleared for clinical use.
    Documentation noteWhen ordering LDT salivary assays, providers should document the assay method (e.g., ELISA or LC‑MS/MS) and clinical rationale because many salivary tests are LDTs.
    Laboratory-developed test (LDT) — CLIA-regulated high-complexity test explanation
    DefinitionLaboratory-developed test (LDT): a test developed and validated by a laboratory and regulated by CMS as a high-complexity test under CLIA '88; LDTs are not approved or cleared by the FDA.
    Regulatory implicationAlthough not FDA-approved, LDTs are permitted for clinical use and must be validated and performed in-house per CLIA requirements.
    Impact on coverage/documentationBecause many salivary hormone assays are LDTs, include test name, methodology, and clinical rationale in documentation to support medical necessity.
    Late-night salivary cortisol (LNSC) — description and Endocrine Society recommendation
    What it measuresLate-night salivary cortisol (LNSC) measures free (unbound) cortisol in saliva collected late at night as a noninvasive screen for hypercortisolism/Cushing syndrome.
    Guideline recommendationEndocrine Society recommends obtaining at least two LNSC measurements for diagnosis and supports LNSC as a first-line biochemical test for suspected Cushing syndrome.
    Clinical roleLNSC may be used for initial screening and in post-operative surveillance (e.g., after transsphenoidal adenomectomy) when eucortisolism is in question.